Anna M. Romanov* and Jeongpyo Hong
Edited by Steven S. Cheng and Grant A. Knappe
Article | Aug. 29 2022
- Human challenge trials are advantageous for studying emerging disease and vaccine efficacy but have a controversial history
- Challenge trials for COVID-19 began in 2021 and invigorated the debate around the ethics of intentionally exposing trial participants
- Few regulations currently exist for challenge agents, possibly limiting implementation in future epidemics
This MIT Science Policy Review article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/ by/4.0/.